[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Zavation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":119},{"warningLetters":4,"total":118},[5,31,53,75,97],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":25,"medical_device_id":20,"response_letter_date":20},2878,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-02-09T20:00:00Z\">02\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-09T05:00:00Z\">02\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fe-cig-innovation-624569-02092022\">E-Cig Innovation\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chris Potvin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>E-Cig Innovation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13912 1st Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Becker\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55308\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:eciginnovation@gmail.com\"> eciginnovation@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 9, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Potvin:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that E-Cig Innovation manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Ecig Innovation Guava 6mg e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 20 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200417, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nChris Potvin\n\nRecipient Title\n\nOwner\n\nE-Cig Innovation\n\n13912 1st Street\n\nBecker, MN 55308\n\nUnited States\n\neciginnovation@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 9, 2022\n\nWARNING LETTER\n\nDear Mr. Potvin:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that E-Cig Innovation manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Ecig Innovation Guava 6mg e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 20 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200417, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","E-Cig Innovation","e-cig-innovation-624569-02092022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fe-cig-innovation-624569-02092022","2026-10-26T08:08:29.087285+00:00","Warning Letter","Issued","2022-02-09","624569","Tobacco","Chris Potvin","2026-08-20T02:11:55.737+00:00","VIA UPS and Electronic Mail",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":52,"medical_device_id":20,"response_letter_date":20},1924,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-18T04:00:00Z\">08\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatures-innovation-inc-648560-08182023\">Nature’s Innovation, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William S. Carlson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nature’s Innovation, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5317 Palmero Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buford\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30518\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@naturesinnovation.com\"> info@naturesinnovation.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 18, 2023\u003C\u002Fp>\n\n\u003Cp>RE: 648560\u003C\u002Fp>\n\n\u003Cp>Dear William Carlson:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.naturasil.com in July 2023. We also reviewed your social media websites at www.instagram.com\u002Fnaturasil\u002F and www.facebook.com\u002FNaturasil\u002F, where you direct consumers to your website, www.naturasil.com, to purchase your products. The FDA has observed that your website offers your “Naturasil Molluscum Treatment Kit”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and “Naturasil Shingles” products for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Molluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. Your “Naturasil Molluscum Treatment Kit” is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\u003C\u002Fp>\n\n\u003Cp>Your “Naturasil Shingles” product is concerning for various reasons. Shingles is a serious condition that is not amenable to either diagnosis or treatment by a lay person, and there are no legally marketed OTC drug products to treat this condition. Treatment of shingles requires antiviral therapy, and early treatment is key to promote healing of the rash and reduce the severity and duration of pain. A person with shingles can potentially spread the varicella-zoster virus to others. Furthermore, FDA is concerned that people who use an unapproved drug product claiming to treat shingles are putting themselves at risk for developing serious complications, e.g., postherpetic neuralgia (long-term nerve pain), herpes zoster ophthalmicus (which can lead to vision loss), and skin infections.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites, your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Naturasil Molluscum Treatment Kit\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “Naturasil Molluscum Treatment Kit,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fmolluscum-contagiosum-treatment-kit?_pos=12&amp;_sid=acf8ae577&amp;_ss=r:\u003Cbr>\n• “NATURASIL FOR MOLLUSCUM IS THE NUMBER 1 All Natural, No Acids, Pain-Free Remedy for Children and Adults, Made in the USA. Parent Approved!”\u003Cbr>\n• “Naturasil for Molluscum Treatment Kit . . . Get rid of Molluscum at home with this PAIN-FREE BREAKTHROUGH 100% Natural Molluscum Contagiosum Treatment. CHILD-SAFE (2 years old &amp; above) Causes Molluscum to dry up and flake away painlessly over time.”\u003Cbr>\n• “Effectively &amp; gently clears Molluscum bumps Relieves itching &amp; discomfort”\u003Cbr>\n• “Naturasil for Molluscum Treatment Kit for Children and Adults… Best for treating Genitals and other sensitive areas and children or adults with large or severe Molluscum outbreaks.”\u003C\u002Fp>\n\n\u003Cp>From a September 6, 2022 blog post entitled, “MOLLUSCUM CONTAGIOSUM | SIGNS AND SYMPTOMS OF AN INFECTION,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fmolluscum-contagiosum-signs-symptoms?_pos=8&amp;_sid=c37dd889d&amp;_ss=r:\u003Cbr>\n• “Regardless, effective natural remedies, such as the Naturasil Molluscum Contagiosum Treatments are designed to penetrate viral cells to quicken your recovery time.”\u003C\u002Fp>\n\n\u003Cp>From a June 10, 2022 blog post entitled, “Natural Treatment Options for Molluscum Contagiosum,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fnatural-treatment-options-for-molluscum-contagiosum?_pos=7&amp;_sid=c37dd889d&amp;_ss=r:\u003Cbr>\n• “Naturasil's Molluscum Contagiosum Treatment was constructed with the most potent ingredients throughout the herbal industry. Each compound injects a vast array of nutrients capable of hindering the health and development of the molluscum virus.”\u003Cbr>\n• “Naturasil for Molluscum is a completely natural treatment solution that eradicates this awful condition often found in children quickly and safely without the use of harsh chemicals.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook social media page https:\u002F\u002Fwww.facebook.com\u002FNaturasil\u002F:\u003Cbr>\n• March 15, 2023 post: “Most Trusted Molluscum Brand Effectively &amp; #gently #clears #Molluscum #bumps #Relieves #itching &amp; #discomfort”\u003Cbr>\n• October 8, 2022 post – Your post includes some of the following hashtags: “#molluscumcontagiosum,” “#kidsafe,” “#natural,” “#remedy,” “#treatment” with an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “I wish I could share before and after photos, his molluscum is almost gone with a few more treatments it will be . . . My 3 year [old] has had it for 1.5 years and nothing worked. Thank you soo [sic] much Naturasil.”\u003C\u002Fp>\n\n\u003Cp>On your Instagram social media page https:\u002F\u002Fwww.instagram.com\u002Fnaturasil\u002F?hl=en:\u003Cbr>\n• August 4, 2022 post – Your post includes an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “It works! We’ve been using the product for a few weeks and I can definitely see an improvement in my daughter’s sports. Some are shrinking and others are drying up. We have had the best results when applying it 4-5 times a day. It requires patience, but is the only thing I’ve seen that works!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Naturasil Shingles\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “Naturasil Shingles,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fshingles-15ml:\u003Cbr>\n• “Naturasil for Shingles assists the body in reducing and eliminating shingles outbreaks naturally and effectively, without the harmful side effects found in many shingles treatment drugs, through a topical application that is absorbed into the skin at the site of the outbreak.”\u003Cbr>\n• “The active components of our shingles treatments are high levels of neral, geraniol, alpha-terpinenes, and linalool. All anti-viral and anti-inflammatory compounds are found in Melissa Officinalis, melaleuca alternifolia, agathophyllum aromatica, and other critical anti-viral plant extracts. These compounds have anti-viral properties and effectively combat the herpes zoster virus that causes shingles.”\u003Cbr>\n• “END THE SHINGLE NIGHTMARE NOW. Get the all-natural, #1 REMEDY, complete package for treating YOUR Shingles.”\u003C\u002Fp>\n\n\u003Cp>Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On your website, www.naturasil.com, you state that your “Naturasil Molluscum Treatment Kit” product consists of your “Naturasil Molluscum Topical Liquid” and your “Naturasil Molluscum Relief Soap” products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “Naturasil Molluscum Treatment Kit” and “Naturasil Shingles” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\n\n\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your above-mentioned drugs include non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted on your website in various places with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam S. Carlson\n\nRecipient Title\n\nCEO\n\nNature’s Innovation, Inc.\n\n5317 Palmero Court\n\nBuford, GA 30518\n\nUnited States\n\ninfo@naturesinnovation.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nAugust 18, 2023\n\nRE: 648560\n\nDear William Carlson:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.naturasil.com in July 2023. We also reviewed your social media websites at www.instagram.com\u002Fnaturasil\u002F and www.facebook.com\u002FNaturasil\u002F, where you direct consumers to your website, www.naturasil.com, to purchase your products. The FDA has observed that your website offers your “Naturasil Molluscum Treatment Kit”1 and “Naturasil Shingles” products for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.\n\nMolluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. Your “Naturasil Molluscum Treatment Kit” is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\n\nYour “Naturasil Shingles” product is concerning for various reasons. Shingles is a serious condition that is not amenable to either diagnosis or treatment by a lay person, and there are no legally marketed OTC drug products to treat this condition. Treatment of shingles requires antiviral therapy, and early treatment is key to promote healing of the rash and reduce the severity and duration of pain. A person with shingles can potentially spread the varicella-zoster virus to others. Furthermore, FDA is concerned that people who use an unapproved drug product claiming to treat shingles are putting themselves at risk for developing serious complications, e.g., postherpetic neuralgia (long-term nerve pain), herpes zoster ophthalmicus (which can lead to vision loss), and skin infections.\n\nUnapproved New Drugs\n\nBased on a review of your websites, your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nNaturasil Molluscum Treatment Kit\n\nOn the product webpage for “Naturasil Molluscum Treatment Kit,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fmolluscum-contagiosum-treatment-kit?_pos=12&_sid=acf8ae577&_ss=r:\n\n• “NATURASIL FOR MOLLUSCUM IS THE NUMBER 1 All Natural, No Acids, Pain-Free Remedy for Children and Adults, Made in the USA. Parent Approved!”\n\n• “Naturasil for Molluscum Treatment Kit . . . Get rid of Molluscum at home with this PAIN-FREE BREAKTHROUGH 100% Natural Molluscum Contagiosum Treatment. CHILD-SAFE (2 years old & above) Causes Molluscum to dry up and flake away painlessly over time.”\n\n• “Effectively & gently clears Molluscum bumps Relieves itching & discomfort”\n\n• “Naturasil for Molluscum Treatment Kit for Children and Adults… Best for treating Genitals and other sensitive areas and children or adults with large or severe Molluscum outbreaks.”\n\nFrom a September 6, 2022 blog post entitled, “MOLLUSCUM CONTAGIOSUM | SIGNS AND SYMPTOMS OF AN INFECTION,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fmolluscum-contagiosum-signs-symptoms?_pos=8&_sid=c37dd889d&_ss=r:\n\n• “Regardless, effective natural remedies, such as the Naturasil Molluscum Contagiosum Treatments are designed to penetrate viral cells to quicken your recovery time.”\n\nFrom a June 10, 2022 blog post entitled, “Natural Treatment Options for Molluscum Contagiosum,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fnatural-treatment-options-for-molluscum-contagiosum?_pos=7&_sid=c37dd889d&_ss=r:\n\n• “Naturasil's Molluscum Contagiosum Treatment was constructed with the most potent ingredients throughout the herbal industry. Each compound injects a vast array of nutrients capable of hindering the health and development of the molluscum virus.”\n\n• “Naturasil for Molluscum is a completely natural treatment solution that eradicates this awful condition often found in children quickly and safely without the use of harsh chemicals.”\n\nOn your Facebook social media page https:\u002F\u002Fwww.facebook.com\u002FNaturasil\u002F:\n\n• March 15, 2023 post: “Most Trusted Molluscum Brand Effectively & #gently #clears #Molluscum #bumps #Relieves #itching & #discomfort”\n\n• October 8, 2022 post – Your post includes some of the following hashtags: “#molluscumcontagiosum,” “#kidsafe,” “#natural,” “#remedy,” “#treatment” with an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “I wish I could share before and after photos, his molluscum is almost gone with a few more treatments it will be . . . My 3 year [old] has had it for 1.5 years and nothing worked. Thank you soo [sic] much Naturasil.”\n\nOn your Instagram social media page https:\u002F\u002Fwww.instagram.com\u002Fnaturasil\u002F?hl=en:\n\n• August 4, 2022 post – Your post includes an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “It works! We’ve been using the product for a few weeks and I can definitely see an improvement in my daughter’s sports. Some are shrinking and others are drying up. We have had the best results when applying it 4-5 times a day. It requires patience, but is the only thing I’ve seen that works!”\n\nNaturasil Shingles\n\nOn the product webpage for “Naturasil Shingles,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fshingles-15ml:\n\n• “Naturasil for Shingles assists the body in reducing and eliminating shingles outbreaks naturally and effectively, without the harmful side effects found in many shingles treatment drugs, through a topical application that is absorbed into the skin at the site of the outbreak.”\n\n• “The active components of our shingles treatments are high levels of neral, geraniol, alpha-terpinenes, and linalool. All anti-viral and anti-inflammatory compounds are found in Melissa Officinalis, melaleuca alternifolia, agathophyllum aromatica, and other critical anti-viral plant extracts. These compounds have anti-viral properties and effectively combat the herpes zoster virus that causes shingles.”\n\n• “END THE SHINGLE NIGHTMARE NOW. Get the all-natural, #1 REMEDY, complete package for treating YOUR Shingles.”\n\nYour “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products.2 Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n__________________________\n\n1 On your website, www.naturasil.com, you state that your “Naturasil Molluscum Treatment Kit” product consists of your “Naturasil Molluscum Topical Liquid” and your “Naturasil Molluscum Relief Soap” products.\n\n2 We recognize that the “Naturasil Molluscum Treatment Kit” and “Naturasil Shingles” labeling describes the products as being “homeopathic.”\n\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your above-mentioned drugs include non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted on your website in various places with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","Nature’s Innovation, Inc.","natures-innovation-inc-648560-08182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatures-innovation-inc-648560-08182023","2026-10-26T08:09:30.91471+00:00","2023-08-22","648560","Drugs","William S. Carlson","2026-08-20T00:46:42.599+00:00","Via Email","2023-08-18",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":24,"posted_date":68,"marcs_cms_no":69,"product_type":48,"closeout_date":20,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":20,"reference_number":73,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},1068,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2025-02-11T05:00:00Z\">02\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-05T05:00:00Z\">02\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-innovation-pharmaceutical-co-ltd-698786-02052025\">Chengdu Innovation Pharmaceutical Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-40\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ren Zhongju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Chengdu Innovation Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No.123, 1st Floor, No 91 Zhongheng Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jinniu Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chengdu Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sichuan Sheng\u003C\u002Fspan>, \u003Cspan>610036\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-40\u003C\u002Fp>\u003Cp>February 5, 2025\u003C\u002Fp>\u003Cp>Dear Ren Zhongju:\u003C\u002Fp>\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our April 29, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Chengdu Innovation Pharmaceutical Co., Ltd., FEI 3027222600, No.123, 1st Floor, No 91 Zhongheng Street, Jinniu District, Chengdu, Sichuan, China.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for API.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant deviations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>704(a)(4) Request for Records and Related CGMP Deviations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to test the identity of each lot of incoming production material.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture APIs that were distributed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the United States. Based on the records and information you provided, you have not demonstrated that you are adequately testing each shipment of each lot of incoming materials. Specifically in response to our request, you state that you do not perform identity testing on each shipment of each lot of incoming material before they are released for use in drug manufacturing.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure of your quality unit to establish a system to release or reject raw materials, intermediates, packaging, and labeling materials.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not establish an appropriate system to approve or reject incoming materials.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including sections on quality oversight. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 17, 2025.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003Cbr>\u003Cbr>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027222600 and ATTN: William Yang.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-40\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRen Zhongju\n\nChengdu Innovation Pharmaceutical Co., Ltd.\n\nNo.123, 1st Floor, No 91 Zhongheng Street\n\nJinniu Qu\n\nChengdu Shi\n\nSichuan Sheng, 610036\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-40\nFebruary 5, 2025\nDear Ren Zhongju:\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our April 29, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Chengdu Innovation Pharmaceutical Co., Ltd., FEI 3027222600, No.123, 1st Floor, No 91 Zhongheng Street, Jinniu District, Chengdu, Sichuan, China.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for API.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant deviations were observed including, but not limited to, the following:\n704(a)(4) Request for Records and Related CGMP Deviations\n1. Failure to test the identity of each lot of incoming production material.\nYou manufacture APIs that were distributed to (b)(4) in the United States. Based on the records and information you provided, you have not demonstrated that you are adequately testing each shipment of each lot of incoming materials. Specifically in response to our request, you state that you do not perform identity testing on each shipment of each lot of incoming material before they are released for use in drug manufacturing.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\nIn response to this letter, provide:\nA description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\nA comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\nA summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\nA summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\n2. Failure of your quality unit to establish a system to release or reject raw materials, intermediates, packaging, and labeling materials.\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not establish an appropriate system to approve or reject incoming materials.\nYour QU is responsible for fully exercising its authority and responsibilities.\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug quality. FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP, including sections on quality oversight. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on January 17, 2025.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any deviations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027222600 and ATTN: William Yang.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Chengdu Innovation Pharmaceutical Co., Ltd.","chengdu-innovation-pharmaceutical-co-ltd-698786-02052025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-innovation-pharmaceutical-co-ltd-698786-02052025","2026-10-26T08:08:14.288167+00:00","2025-02-11","698786","Ren Zhongju","2026-08-19T17:02:27.799+00:00","VIA Electronic Mail","320-25-40","2025-02-05",{"id":76,"raw":77,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":65,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":24,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":20,"issuing_office":81,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":20,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},1388,[78,79,80,81,82,13,13,13],"\u003Ctime datetime=\"2024-07-09T13:20:00Z\">07\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-20T04:00:00Z\">06\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024\">New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\u003C\u002Fa>","Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey L. Millea\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2501 Yale Boulevard SE, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Jeffrey.Millea@corneagen.com\"> Jeffrey.Millea@corneagen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 20, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter OBPO 24-681776\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Millea:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, New Mexico Lions Sight Conservation Foundation, Inc., also doing business as New Mexico Lions Eye Bank, located at 2501 Yale Boulevard SE, Suite 100, Albuquerque, NM, conducted between February 23 and February 28, 2024, the United States Food and Drug Administration (FDA) documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21 Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)]. \u003C\u002Fstrong>You failed to determine as ineligible two donors of ocular HCT\u002FPs with a documented diagnosis or clinical evidence of sepsis, including two or more systemic responses to infection, documented within their available medical records during the hospital stay immediately preceding death. For example:\u003C\u002Fp>\n\n\u003Cp>a. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 2\u002F5\u002F24, and ocular HCT\u002FPs from the donor were distributed on 2\u002F1\u002F24.\u003C\u002Fp>\n\n\u003Cp>The donor was taken to the Emergency Department (ED) on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and was found to have altered mental status, hypothermia, hypotension, leukocytosis, and lactic acidosis, among other serious medical conditions. The donor was diagnosed with urosepsis and treated with three renally dosed antibiotics and was admitted to the Intensive Care Unit (ICU) for sepsis and septic shock. The donor continued to decline and expired on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> had a diagnosis of sepsis (urosepsis), risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Urinary tract infection (urine culture from 1\u002F29\u002F24 grew more than 100,000 cfu\u002FmL of more than two microorganisms);\u003C\u002Fli>\n\t\u003Cli>Elevated White Blood Cell (WBC) count &gt;12,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup> (21,700 cells\u002Fmm\u003Csup>3\u003C\u002Fsup> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Respiratory rate &gt;20 breaths\u002Fminute (26 breaths\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Heart rate &gt;90 beats\u002Fminute (99 beats\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Altered mental status;\u003C\u002Fli>\n\t\u003Cli>Lactic acidosis; and\u003C\u002Fli>\n\t\u003Cli>Hypotension.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F6\u002F23, and ocular HCT\u002FPs from the donor were distributed on 3\u002F2\u002F23.\u003C\u002Fp>\n\n\u003Cp>The donor presented in the ED on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> with acute hypoxic respiratory failure, decreased tissue perfusion, tachycardia, tachypnea, and hypertension. Not long after arriving in the ED, the donor’s systolic blood pressure dropped in the 50s mmHg, which is described as the medical center’s “sepsis protocol.” Despite treatment with intravenous fluids, antibiotics, and norepinephrine, the donor continued to decline and expired on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. According to documentation in the medical records, the donor’s primary cause of death is listed as septic shock, with a secondary cause of death as acute hypoxic respiratory failure.\u003C\u002Fp>\n\n\u003Cp>Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> had a diagnosis of sepsis and septic shock, risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>WBC count &gt;12,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup>, &lt;4,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup>, or band forms &gt;10% (donor had left shift of 88.3% neutrophils and 53% band forms on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Respiratory rate &gt;20 breaths\u002Fminute (36 breaths\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Heart rate &gt;90 beats\u002Fminute (137 beats\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Elevated serum creatinine (2.4 mg\u002FdL on 2\u002F28\u002F23 (0.5-1.5mg\u002FdL reference range)) indicating acute kidney injury;\u003C\u002Fli>\n\t\u003Cli>Acute hypoxic respiratory failure;\u003C\u002Fli>\n\t\u003Cli>Altered mental status; and\u003C\u002Fli>\n\t\u003Cli>Systolic blood pressure dropped to 50 mmHg.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The events described above are HCT\u002FP deviations related to core Current Good Tissue Practice (CGTP) requirements and must be investigated and documented. Because these situations represent an HCT\u002FP deviation relating to a core CGTP and to the prevention of communicable disease transmission or HCT\u002FP contamination; and HCT\u002FPs were distributed, deviation reports must be submitted to FDA in accordance with 21 CFR 1271.350(b).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to ensure procedures are in compliance with the donor eligibility requirements within Subpart C – Donor Eligibility of 21 CFR Part 1271 [21 CFR 1271.47(a)].\u003C\u002Fstrong> For example, your procedures, “T-710 Donor Screening Criteria,” “TF-710-01 Donor Screening Criteria Guide,” and “T-720 Donor Eligibility Determination,” are used to determine donor eligibility, and “TF-710-02 Sepsis Algorithm,” is used to determine a donor’s risk for sepsis and if an infectious disease consult is required. These procedures fail to include all clinical evidence and systemic responses to infection, if unexplained, of sepsis during the donor’s hospital stay immediately preceding death to appropriately evaluate a donor’s sepsis risk. Additionally, your procedures fail to include systemic responses to infection of sepsis such as a heart rate &gt;90 beats\u002Fminute, partial pressure of carbon dioxide (PaCO2) &lt;32\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, and more severe signs of sepsis, such as unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension.\u003C\u002Fp>\n\n\u003Cp>Both donors referenced above were evaluated for a risk of sepsis using the “TF-710-02 Sepsis Algorithm.” Documentation in the donor records included the following standard statement that failed to take into account all the clinical evidence of sepsis and systemic responses to infection as documented in the medical records during the hospital stay immediately preceding death:\u003C\u002Fp>\n\n\u003Cp>“As long as these were all the clinical ID tests drawn (or the only ID studies done) (blood, sputum, urine, peritoneal fluid, CSF, AFB Cxs; viral tests; Quantiferon, etc) there was no definitive empirical evidence of sepsis or bacteremia at TOD.”\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter, dated March 20, 2024, providing a response to the FDA’s inspectional observations. We have reviewed your response and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\u003C\u002Fp>\n\n\u003Cp>1. In response to Observation 1, your disagreement that the donors were septic at the time of the death does not account for the donors’ medical records with documented diagnoses and clinical evidence of sepsis, including systemic responses to infection, during their hospital stay immediately preceding death. Your response states, “Quite simply, one cannot be septic and have negative blood cultures. And the practice of paper sepsis has proven over and over and over and over to be an inaccurate characterization of sepsis. At the same time the active problem list carries over “sepsis” the individual has no elevated temp and has 2 sets of no growth blood cultures. Prior to 2009, this individual would not have sepsis listed on their active problem list because the no growth blood cultures prove the patient is not septic! Fast forward to 2009 and a line has been drawn in the sand and most patients on admit are all of a sudden septic?! We respectfully challenge the FDA to please follow the logic here.”\u003C\u002Fp>\n\n\u003Cp>Regardless of the year, the donors would have been diagnosed with sepsis based on clinical presentation and laboratory data. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A diagnosis of sepsis can be made in the emergency room and positive blood cultures are not required for the diagnosis of sepsis.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Positive pre-mortem blood cultures \u003Cstrong>may\u003C\u002Fstrong> be associated with clinical evidence of sepsis. However, negative blood cultures do not exclude a diagnosis of bacteremia or sepsis. Routine blood cultures do not identify all microbial agents that can cause sepsis and additional incubation time, or special media is sometimes needed. Previous administration of antibiotics is frequently a reason for negative blood cultures (i.e., culture negative sepsis)\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. There are a myriad of reasons why blood cultures may be negative in cases of sepsis, and the absence of a positive blood culture does not exclude sepsis as a cause of death.\u003C\u002Fp>\n\n\u003Cp>Additionally, in FDA’s Guidance for Industry: Eligibility Determination of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (August 2007), the Agency describes our current thinking on the risks of sepsis in deceased donors to include a review of medical records during a hospital stay immediately preceding death for diagnosis of sepsis, clinical evidence of infection, and systemic responses to infection. These risk factors for sepsis and septic shock are supported in recent medical literature.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>2. Your response to Observation 2 states your current written procedures meet FDA regulatory requirements for evaluating clinical signs\u002Fsymptoms of sepsis. However, your procedures and algorithm do not account for the diagnosis or clinical evidence of sepsis, including systemic responses to infection, during a hospital stay immediately preceding death. They also do not include more severe signs of sepsis, for example, unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension per FDA guidance referenced above. We note that a donor must be determined ineligible if there is documented diagnosis and clinical evidence of sepsis, including systemic responses to infection, documented in their medical records during a hospital stay immediately preceding death regardless of whether that information is documented within five days of death.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction has been achieved. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Evans, L. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11): e1063-e1143\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Scheer, CS. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect. 2019 Mar; 25(3):326-331.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJeffrey L. Millea\n\nRecipient Title\n\nExecutive Director\n\nNew Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\n\n2501 Yale Boulevard SE, Suite 100\n\nAlbuquerque, NM 87106\n\nUnited States\n\nJeffrey.Millea@corneagen.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nJune 20, 2024\n\nWarning Letter OBPO 24-681776\n\nDear Mr. Millea:\n\nDuring an inspection of your firm, New Mexico Lions Sight Conservation Foundation, Inc., also doing business as New Mexico Lions Eye Bank, located at 2501 Yale Boulevard SE, Suite 100, Albuquerque, NM, conducted between February 23 and February 28, 2024, the United States Food and Drug Administration (FDA) documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21 Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)]. You failed to determine as ineligible two donors of ocular HCT\u002FPs with a documented diagnosis or clinical evidence of sepsis, including two or more systemic responses to infection, documented within their available medical records during the hospital stay immediately preceding death. For example:\n\na. Donor (b)(6), (b)(7)(C) was determined eligible on 2\u002F5\u002F24, and ocular HCT\u002FPs from the donor were distributed on 2\u002F1\u002F24.\n\nThe donor was taken to the Emergency Department (ED) on (b)(6), (b)(7)(C) and was found to have altered mental status, hypothermia, hypotension, leukocytosis, and lactic acidosis, among other serious medical conditions. The donor was diagnosed with urosepsis and treated with three renally dosed antibiotics and was admitted to the Intensive Care Unit (ICU) for sepsis and septic shock. The donor continued to decline and expired on (b)(6), (b)(7)(C).\n\nDonor (b)(6), (b)(7)(C) had a diagnosis of sepsis (urosepsis), risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\n\nUrinary tract infection (urine culture from 1\u002F29\u002F24 grew more than 100,000 cfu\u002FmL of more than two microorganisms);\n\nElevated White Blood Cell (WBC) count >12,000 cells\u002Fmm3 (21,700 cells\u002Fmm3 on (b)(6), (b)(7)(C));\n\nRespiratory rate >20 breaths\u002Fminute (26 breaths\u002Fminute on (b)(6), (b)(7)(C));\n\nHeart rate >90 beats\u002Fminute (99 beats\u002Fminute on (b)(6), (b)(7)(C));\n\nAltered mental status;\n\nLactic acidosis; and\n\nHypotension.\n\nb. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F6\u002F23, and ocular HCT\u002FPs from the donor were distributed on 3\u002F2\u002F23.\n\nThe donor presented in the ED on (b)(6), (b)(7)(C) with acute hypoxic respiratory failure, decreased tissue perfusion, tachycardia, tachypnea, and hypertension. Not long after arriving in the ED, the donor’s systolic blood pressure dropped in the 50s mmHg, which is described as the medical center’s “sepsis protocol.” Despite treatment with intravenous fluids, antibiotics, and norepinephrine, the donor continued to decline and expired on (b)(6), (b)(7)(C). According to documentation in the medical records, the donor’s primary cause of death is listed as septic shock, with a secondary cause of death as acute hypoxic respiratory failure.\n\nDonor (b)(6), (b)(7)(C) had a diagnosis of sepsis and septic shock, risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\n\nWBC count >12,000 cells\u002Fmm3, \u003C4,000 cells\u002Fmm3, or band forms >10% (donor had left shift of 88.3% neutrophils and 53% band forms on (b)(6), (b)(7)(C));\n\nRespiratory rate >20 breaths\u002Fminute (36 breaths\u002Fminute on (b)(6), (b)(7)(C));\n\nHeart rate >90 beats\u002Fminute (137 beats\u002Fminute on (b)(6), (b)(7)(C));\n\nElevated serum creatinine (2.4 mg\u002FdL on 2\u002F28\u002F23 (0.5-1.5mg\u002FdL reference range)) indicating acute kidney injury;\n\nAcute hypoxic respiratory failure;\n\nAltered mental status; and\n\nSystolic blood pressure dropped to 50 mmHg.\n\nThe events described above are HCT\u002FP deviations related to core Current Good Tissue Practice (CGTP) requirements and must be investigated and documented. Because these situations represent an HCT\u002FP deviation relating to a core CGTP and to the prevention of communicable disease transmission or HCT\u002FP contamination; and HCT\u002FPs were distributed, deviation reports must be submitted to FDA in accordance with 21 CFR 1271.350(b).\n\n2. Failure to ensure procedures are in compliance with the donor eligibility requirements within Subpart C – Donor Eligibility of 21 CFR Part 1271 [21 CFR 1271.47(a)]. For example, your procedures, “T-710 Donor Screening Criteria,” “TF-710-01 Donor Screening Criteria Guide,” and “T-720 Donor Eligibility Determination,” are used to determine donor eligibility, and “TF-710-02 Sepsis Algorithm,” is used to determine a donor’s risk for sepsis and if an infectious disease consult is required. These procedures fail to include all clinical evidence and systemic responses to infection, if unexplained, of sepsis during the donor’s hospital stay immediately preceding death to appropriately evaluate a donor’s sepsis risk. Additionally, your procedures fail to include systemic responses to infection of sepsis such as a heart rate >90 beats\u002Fminute, partial pressure of carbon dioxide (PaCO2) \u003C321, and more severe signs of sepsis, such as unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension.\n\nBoth donors referenced above were evaluated for a risk of sepsis using the “TF-710-02 Sepsis Algorithm.” Documentation in the donor records included the following standard statement that failed to take into account all the clinical evidence of sepsis and systemic responses to infection as documented in the medical records during the hospital stay immediately preceding death:\n\n“As long as these were all the clinical ID tests drawn (or the only ID studies done) (blood, sputum, urine, peritoneal fluid, CSF, AFB Cxs; viral tests; Quantiferon, etc) there was no definitive empirical evidence of sepsis or bacteremia at TOD.”\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with the law.\n\nWe acknowledge receipt of your letter, dated March 20, 2024, providing a response to the FDA’s inspectional observations. We have reviewed your response and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\n\n1. In response to Observation 1, your disagreement that the donors were septic at the time of the death does not account for the donors’ medical records with documented diagnoses and clinical evidence of sepsis, including systemic responses to infection, during their hospital stay immediately preceding death. Your response states, “Quite simply, one cannot be septic and have negative blood cultures. And the practice of paper sepsis has proven over and over and over and over to be an inaccurate characterization of sepsis. At the same time the active problem list carries over “sepsis” the individual has no elevated temp and has 2 sets of no growth blood cultures. Prior to 2009, this individual would not have sepsis listed on their active problem list because the no growth blood cultures prove the patient is not septic! Fast forward to 2009 and a line has been drawn in the sand and most patients on admit are all of a sudden septic?! We respectfully challenge the FDA to please follow the logic here.”\n\nRegardless of the year, the donors would have been diagnosed with sepsis based on clinical presentation and laboratory data. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.1-2 A diagnosis of sepsis can be made in the emergency room and positive blood cultures are not required for the diagnosis of sepsis.1-2 Positive pre-mortem blood cultures may be associated with clinical evidence of sepsis. However, negative blood cultures do not exclude a diagnosis of bacteremia or sepsis. Routine blood cultures do not identify all microbial agents that can cause sepsis and additional incubation time, or special media is sometimes needed. Previous administration of antibiotics is frequently a reason for negative blood cultures (i.e., culture negative sepsis)3. There are a myriad of reasons why blood cultures may be negative in cases of sepsis, and the absence of a positive blood culture does not exclude sepsis as a cause of death.\n\nAdditionally, in FDA’s Guidance for Industry: Eligibility Determination of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (August 2007), the Agency describes our current thinking on the risks of sepsis in deceased donors to include a review of medical records during a hospital stay immediately preceding death for diagnosis of sepsis, clinical evidence of infection, and systemic responses to infection. These risk factors for sepsis and septic shock are supported in recent medical literature.1-2\n\n2. Your response to Observation 2 states your current written procedures meet FDA regulatory requirements for evaluating clinical signs\u002Fsymptoms of sepsis. However, your procedures and algorithm do not account for the diagnosis or clinical evidence of sepsis, including systemic responses to infection, during a hospital stay immediately preceding death. They also do not include more severe signs of sepsis, for example, unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension per FDA guidance referenced above. We note that a donor must be determined ineligible if there is documented diagnosis and clinical evidence of sepsis, including systemic responses to infection, documented in their medical records during a hospital stay immediately preceding death regardless of whether that information is documented within five days of death.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction has been achieved. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n_______________________\n\n1 Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810.\n\n2 Evans, L. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11): e1063-e1143\n\n3 Scheer, CS. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect. 2019 Mar; 25(3):326-331.","New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank","new-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024","2026-10-26T08:09:32.559365+00:00","2024-07-09","681776","Biologics","Jeffrey L. Millea","2026-08-19T23:59:24.176+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-06-20",{"id":98,"raw":99,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":20,"letter_url":109,"updated_at":110,"action_type":23,"case_status":24,"posted_date":111,"marcs_cms_no":112,"product_type":48,"closeout_date":20,"issuing_office":59,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":20,"reference_number":116,"action_taken_date":117,"medical_device_id":20,"response_letter_date":20},131,[100,101,102,59,103,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026\">HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-05-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leah R. Hanson, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Neuroscience Research\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>295 Phalen Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55130-2455\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-05-02\u003C\u002Fp>\u003Cp>Dear Dr. Hanson:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for sponsor-investigator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (formerly performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, the protocol and final study report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated that the test article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4) \u003C\u002Fstrong>(0.5 mg, 5 mg, and 10 mg, respectively), and for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot used in study \u003Cstrong>(b)(4)\u003C\u002Fstrong>; (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.&nbsp;\u003C\u002Fp>\u003Cp>In addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Your testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations were not accurately documented in the final study report:\u003C\u002Fp>\u003Cp>a. The deaths of two male rats (Rats #41 and #42 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group) during the conduct of the study were not reflected in the final study report.\u003C\u002Fp>\u003Cp>b. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group.\u003C\u002Fp>\u003Cp>c. Female Rat #84 in the 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Testing facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, during the conduct of nonclinical laboratory studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\u003C\u002Fp>\u003Cul>\u003Cli>Hematology test results for male and female rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Serum chemistry test results for male rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hematology test results for male and female rabbits for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> or rabbit blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\u003C\u002Fp>\u003Cp>a. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\u003C\u002Fp>\u003Cp>b. Test system observations\u003C\u002Fp>\u003Cp>c. Laboratory tests\u003C\u002Fp>\u003Cp>d. Handling of animals found to be moribund or dead during a study\u003C\u002Fp>\u003Cp>e. Collection and identification of specimens\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs \u003Cem>before\u003C\u002Fem> conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\u003C\u002Fp>\u003Cp>As evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>05\u002F19\u002F2026 12:58:47 PM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-05-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeah R. Hanson, Ph.D.\n\nRecipient Title\n\nSenior Director, Neuroscience Research\n\nHealthPartners Neuroscience Center Research and Innovation\n\n295 Phalen Boulevard\n\nSaint Paul, MN 55130-2455\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-05-02\nDear Dr. Hanson:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug (b)(4), performed for sponsor-investigator (b)(4) (formerly performed for (b)(4)).\nProtocol (b)(4): “(b)(4)”\nProtocol (b)(4): “(b)(4)”\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\n1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\nThe testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\nSpecifically, the protocol and final study report for Study (b)(4) stated that the test article, (b)(4), was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% (b)(4) (0.5 mg, 5 mg, and 10 mg, respectively), and for Study (b)(4), to a final dose concentration of 1%, 10%, or 20% (b)(4) (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies (b)(4) and (b)(4).\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the (b)(4) lot used in study (b)(4); (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.\nIn addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\nYour testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\n2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol (b)(4), the following observations were not accurately documented in the final study report:\na. The deaths of two male rats (Rats #41 and #42 in the 10% (b)(4) dosing group) during the conduct of the study were not reflected in the final study report.\nb. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% (b)(4) dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% (b)(4) dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% (b)(4) dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% (b)(4) dosing group.\nc. Female Rat #84 in the 20% (b)(4) dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\nIn your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\nTesting facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\nSpecifically, during the conduct of nonclinical laboratory studies (b)(4) and (b)(4), the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\nHematology test results for male and female rats for Protocol (b)(4)\nSerum chemistry test results for male rats for Protocol (b)(4)\nHematology test results for male and female rabbits for Protocol (b)(4)\nAdditionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol (b)(4) or rabbit blood in Protocol (b)(4).\nWe acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol (b)(4). Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\nIn your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\nWhile we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\nA testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\na. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\nb. Test system observations\nc. Laboratory tests\nd. Handling of animals found to be moribund or dead during a study\ne. Collection and identification of specimens\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs before conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\nAs evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n05\u002F19\u002F2026 12:58:47 PM","HealthPartners Neuroscience Center Research and Innovation","healthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-10-26T08:08:53.733946+00:00","2026-06-02","725333","Leah R. Hanson, Ph.D.","2026-08-19T04:39:07.121+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-05-02","2026-05-19",5,{"510k":120,"classification":121,"enforcement":122,"event":123,"event_backfill":124,"pma":125,"warning_letter":126},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]